Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results

被引：79

作者：

Manosuthi, W ^{[1
]}

Kiertiburanakul, S

Sungkanuparph, S

Ruxrungtham, M

Vibhagool, A

Rattanasiri, S

Thakkinstian, A

机构：

[1] Minist Publ Hlth, Bamrasnaradura Inst, Nonthaburi, Thailand

[2] Mahidol Univ, Ramathibodi Hosp, Fac Med, Bangkok 10700, Thailand

[3] HIV Netherlands Australia Thailand HIV NAT Res Co, Thai Red Cross AIDS Res Ctr, Bangkok, Thailand

来源：

AIDS | 2006年 / 20卷 / 01期

关键词：

D O I：

10.1097/01.aids.0000196181.18916.9b

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The potential of drug-drug interaction between efavirenz and rifampicin is a major concern in the treatment of HIV and tuberculosis. The optimal efavirenz dosage is still unclear. Our randomized control trial study recently reported the similar efavirenz level between efavirenz 600 and 800 mg/day in HIV-infected patients receiving rifampicin. We report the similar virological and immunological outcomes at 48 weeks between the two groups. Efavirenz 600 mg/day should be sufficient for concurrent use with rifamipicin.

引用

页码：131 / 132

页数：2

共 8 条

[1]

BARTLETT JG, 2005, GUIDELINES USING ANT

[2]

BENEDEK I, 1998, 12 INT C AIDS GEN JU

[3] Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all [J].

Brennan-Benson, P ;

Lyus, R ;

Harrison, T ;

Pakianathan, M ;

Macallan, D .

AIDS, 2005, 19 (14) :1541-1543

[4] Power and sample size calculations for studies involving linear regression [J].

Dupont, WD ;

Plummer, WD .

CONTROLLED CLINICAL TRIALS, 1998, 19 (06) :589-601

[5] Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin [J].

Li, AP ;

Reith, MK ;

Rasmussen, A ;

Gorski, JC ;

Hall, SD ;

Xu, L ;

Kaminski, DL ;

Cheng, LK .

CHEMICO-BIOLOGICAL INTERACTIONS, 1997, 107 (1-2) :17-30

[6] Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis [J].

Lopez-Cortes L.F. ;

Ruiz-Valderas R. ;

Pompyo V. ;

Aristides A.-G. ;

Gomez-Mateos J. ;

Leon-Jimenez E. ;

Sarasa-Nacenta M. ;

Lopez-Pua Y. ;

Pachon J. .

Clinical Pharmacokinetics, 2002, 41 (9) :681-690

[7] Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin [J].

Manosuthi, W ;

Sungkanuparph, S ;

Thakkinstian, A ;

Vibhagool, A ;

Kiertiburanakul, S ;

Rattanasiri, S ;

Prasithsirikul, W ;

Sankote, J ;

Mahanontharit, A ;

Ruxrungtham, K .

AIDS, 2005, 19 (14) :1481-1486

[8] Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans [J].

Mouly, S ;

Lown, KS ;

Kornhauser, D ;

Joseph, JL ;

Fiske, WD ;

Benedek, IH ;

Watkins, PB .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (01) :1-9

← 1 →